The arrival of Retatrutide ZPHC, at a concentration of 120mg, is generating considerable buzz within the healthcare community. This novel dual GIP and GLP-1 agonist medication seems to provide significant improvements in body shedding compared to previous therapies. Early clinical trials have ind